Observational studyMedical archives (Sarajevo, Bosnia and Herzegovina)2025
The Role of Amiodarone in the Prevention of Postoperative Atrial Fibrillation After Surgical Myocardial Revascularization.
Observational study in Medical archives (Sarajevo, Bosnia and Herzegovina), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative atrial fibrillation (POAF) is the most common complication after cardiac surgery, increasing morbidity, ICU stay, dialysis need, hospitalization length, and costs. Despite prophylactic strategies, POAF incidence remains high, especially in moderate and high risk patients. Objective: To assess the effect of amiodarone on POAF incidence and onset timing in moderate and high risk patients. Methods: This prospective observational study included 454 patients undergoing elective coronary artery bypass grafting (CABG). Risk stratification of patients was based on the McSPI AFRisk Index, compared with the POAF Score and CHA2DS2-VASc Score. Moderate and high risk patients received amiodarone in combination with beta blockers (Amiodarone group), while low risk patients received beta blockers only. The primary outcome was POAF incidence, analyzed via Kaplan-Meier and Cox regression. Secondary analysis compared POAF rates between groups using the χ2 test. Results: POAF occurred in 5.95% of the Amiodarone group versus 9.25% in the beta blocker group (overall incidence: 15.2%). The relative risk reduction was 27% (RR = 0.27, 95% CI = 0.105-0.689, p = 0.006). POAF incidence was significantly lower in the Amiodarone group (p = 0.008, χ2 test). Kaplan-Meier analysis showed delayed POAF onset in the Amiodarone group (median: 48h vs. 33h, p = 0.0007). Cox regression confirmed a 73% lower risk of early POAF (HR = 0.27, 95% CI = 0.105-0.689, p = 0.006). Conclusion: Amiodarone combined with beta blockers reduces POAF incidence and delays its onset after CABG. Keywords: POAF, CABG, amiodarone, risk stratification. Keywords: Body Dysmorphia, PCOS patients, prevalence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.